![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA APPROVES LESS POTENT FORMULA OF ALPHAGAN GLAUCOMA TREATMENT
FDA APPROVES LESS POTENT FORMULA OF ALPHAGAN GLAUCOMA TREATMENT
August 22, 2005
Allergan announced that the FDA has approved a less potent version of its Alphagan drug to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
The new formulation of Alphagan contains 0.1 percent of the active ingredient, brimonidine tartrate ophthalmic solution, while the original Alphagan contains 0.2 percent.
Open-angle glaucoma is the most common form of glaucoma, and is characterized by pressure of the fluids inside the eye, optic nerve damage and visual field loss.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct